New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Atacand
Synonyms :
Candesartan cilexetil
Class :
Cardiovascular agent, Renin-angiotensin syste m inhibitor, Angiotensin II receptor antagonist, Antihypertensive
Brand Name :
Atacand
Synonyms :
Candesartan cilexetil
Class :
Cardiovascular agent, Renin-angiotensin syste m inhibitor, Angiotensin II receptor antagonist, Antihypertensive
Dosage Forms & Strengths
Tablet
8 mg
8
mg
Tablet
Orally
once a day
once daily is the recommended starting dose and the typical dose that is maintained. Within four weeks, most of the antihypertensive impact is achieved
In certain people, the dose may be raised to 16 mg per day, with an upper limit of 32 mg once each day, if the BP is not sufficiently regulated
It is essential to modify therapy based on the blood pressure response
It is also possible to combine this with other antihypertensive medications
Varying dosages of this medication have been demonstrated to have an additional antihypertensive effect when hydrochlorothiazide is added
Dosage Forms & Strengths
Tablet
8 mg
Youngsters and teenagers from six to under eighteen:
Four milligrams per day is the suggested starting dose.
• For those under 50 kg: If the patient's blood pressure is not sufficiently under control, the amount may be increased up to a daily maximum of 8 mg
• For individuals weighing more than fifty kilograms: If the patient's BP is not sufficiently regulated, the dose may be increased to eight milligrams once daily and, if necessary, to sixteen milligrams per day
Dosage Forms & Strengths
Tablet
8 mg
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the hyperkalemic effect of aliskiren
may enhance the serum concentration of angiotensin II receptor blockers
may increase the hyperkalemic effect of aliskiren
may increase the adverse effect of angiotensin II receptor blockers
it may either increases toxicity of the other by pharmacodynamic synergism
it increases the toxicity of angiotensin II receptor blockers
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
may diminish the therapeutic effect of angiotensin II Receptor Blockers
may diminish the therapeutic effect of angiotensin II Receptor Blockers
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
may enhance the risk of adverse/toxic effect of NSAIDs
It may enhance the effects when combined with maitake by pharmacodynamic synergism
spironolactone and hydrochlorothiazide
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with NSAIDs
candesartan cilexetil: it may increase the hypotensive activities of oxprenolol
the risk of adverse effects may be increased
the rate of metabolism of candesartan cilexetil may be increased
the rate of metabolism of atrocities may be decreased
an increase in hypotensive activity of acebutolol may be seen
the risk of hypertension, renal failure, and hypokalemia may be increased
the risk of hypertension, renal failure, and hypokalemia may be increased
the rate of metabolism of candesartan cilexetil may be reduced
the risk of hypertension, renal failure, and hypokalemia may be increased
the rate of metabolism of candesartan cilexetil may be reduced
the rate of metabolism of candesartan cilexetil may be reduced
the risk of hypertension, renal failure, and hypokalemia may be increased
the risk of adverse effects may be increased
the antihypertensive activity of candesartan cilexetil may be reduced
the rate of metabolism of almotriptan may be reduced
the risk of hyperkalemia and hypotension may be increased
the hypotensive activity of ambrisentan may be increased
the rate of metabolism of amitriptyline may be reduced
the hypotensive activity of candesartan cilexetil may be increased
may have an increasingly adverse effect when combined with NSAIDs
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of finerenone
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
angiotensin II receptor blockers increase the toxicity of NSAIDs
it increases the toxicity of angiotensin II receptor blockers
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may increase the orthostatic hypotensive effect of dapoxetine
may decrease the therapeutic effect of angiotensin-converting enzyme inhibitors
may decreases the therapeutic effect. Angiotensin receptor
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
drospirenone/ethinyl estradiol/levomefolate
may increase the hyperkalemic effect of Drospirenone-Containing Products
polyethylene glycol and electrolytes
It may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
finerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
nicorandil: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
tacrolimus: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
trimethoprim: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hyperkalemic effect when combined with angiotensin II receptor blockers
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may enhance the serum concentration of angiotensin ii receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
Actions and spectrum:
Candesartan stops angiotensin II from binding to AT1 receptors in the adrenal glands and blood vessel walls. This lowers blood pressure by stopping angiotensin II’s effects: constricting blood vessels and increasing aldosterone.
Candesartan is very selective for AT1 over AT2 receptors, more than 10,000 times more selective. This can change how much potassium is excreted. Sodium and water excretion may increase because aldosterone secretion is blocked.
Frequency not defined
Tiredness
Sore throat
Dizziness
Nausea
Pain in the chest
Loss of movement
Lowered urination
Shortness of breath
lightheadedness
Contraindication/Caution:
Contraindication:
Hypersensitivity
Caution:
Renal impairment
Liver impairment
Pregnancy
Breastfeeding
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Lactation:
Data about the excretion of candesartan cilexetil into human milk is not available.
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
<b>Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Candesartan prevents blood vessels from narrowing. It belongs to a class called ARBs, or angiotensin receptor blockers. ARBs target receptors involved in constricting blood vessels. By hindering these receptors, candesartan counteracts constrictive effects on vessels, allowing them to relax and widen. Expanded vessels encounter less resistance, which decreases blood pressure. Doctors utilize this medication for hypertension, heart failure, and cardiovascular conditions, aiming to bolster patients’ health outcomes.
Pharmacodynamics:
Candesartan cilexetil gets absorbed in the gut. It converts to candesartan, the active form. Candesartan is crucial, as an antagonist in the renin-angiotensin system. Antagonists block angiotensin II’s action. This hormone makes blood vessels constrict, raising blood pressure. Blocking angiotensin II helps relax vessels, reducing resistance and lowering blood pressure. So, converting candesartan cilexetil to candesartan allows its effects in treating hypertension.
Pharmacokinetics:
Absorption
The bioavailability of candesartan cilexetil doesn’t get impacted by a high-fat diet, remaining at 15%. A small portion, around 15%, is absorbed.
Distribution
Candesartan is highly bound to plasma proteins, over 99%. Its volume of distribution is 0.13L/kg, indicating extensive tissue binding.
Metabolism
Candesartan cilexetil rapidly converts to candesartan by intestinal enzymes. Candesartan undergoes minor hepatic metabolism, less than 20%, forming an inactive byproduct. UGT1A3 enzyme N-glucuronidates candesartan’s tetrazole ring.
Elimination and excretion
Approximately 26% of the oral dose is eliminated unchanged in urine. Most elimination occurs via urine and feces. Candesartan has a half-life of 9 hours.
Administration:
Candesartan cilexetil has to be taken regularly with or without food.
Patient information leaflet
Generic Name: candesartan cilexetil
Pronounced: kan-de-SAR-tan si-LEX-e-til
Why do we use candesartan cilexetil amic?
Candesartan cilexetil stops blood vessels from narrowing. This helps lower high blood pressure. With it, people won’t get stroke, heart issues, or kidney problems. Candesartan works by blocking a substance that makes vessels tighten. Doctors use it for patients with hypertension. But it can treat other conditions too. Like heart failure or kidney disease from diabetes. Even people at high risk of stroke may take it. Especially if their blood pressure stays up. Overall, candesartan stops serious complications. It’s vital for managing hypertension safely.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
